We retrospectively reviewed factors that affected overall survival for patients with gynecological cancers that had metastasized to the brain. Between January 1985 to November 1999, we treated 25 patients with brain metastases from gynecological malignancies (cervix n=6, endometrium n=10, and ovary n=9). Various patient and tumor characteristics were identified and analyzed for their significance. Median age was 46 years old (range, 37-78 years) with the majority of tumors being adenocarcinoma (20/25 patients). The treatment consisted of whole brain radiation therapy (WBRT) in 11 patients, focal therapy (surgery and/or stereotactic radiosurgery [SRS]) in 6 patients, and combination therapy (WBRT and surgery and/or SRS) in 8 patients and resulted in median survivals of 6 months, 7 months and 11 months, respectively. Overall median survival was 7.3 months (range, 1 to 88 months). Cause of death was systemic in 9, neurologic in 8 and progression of primary in 2.
Introduction
Brain metastases (BM) from gynecological malignancies are considered to be rare. In the few studies that have been written on this subject, no more than 3% of brain metastases were attributable to gynecological tumors. Other studies have shown that they account for no more than 5% of all central nervous system metastases (1, (5) (6) (7) (8) (9) (10) (11) (12) . However, it is difficult to know the exact prevalence of this disease because symptoms are not always present. Autopsy studies have shown that 0.8% to 15% of patients with cervical carcinoma had brain metastases at death (7-9). A study that analyzed brain metastases from endometrial carcinoma reported an incidence of 5% at autopsy (10), while most clinical studies reported much lower incidences (1, 3, 6) .
The most common gynecological malignancy to metastasize to the brain is choriocarcinoma, which accounts for up to 35% of all BM from gynecological cancers (11, 12) . Another paper from summarized 15 studies and reported that the most common primary tumor site is the ovary followed by choriocarcinoma and endometrial carcinoma.
Although the true incidence may not be known, we do know that brain metastases from gynecologic tumors usually occur in patients with widely disseminated disease, and that tumors usually disseminate through the bloodstream after they have implanted on the peritoneal surface, or spread through the lymphatic system (1-6, 10). Write et al. (14) suggested that hematogenous spread of cervical carcinoma occurs first in the lungs and then in the brain.
Although BM from gynecological carcinoma are rare, the incidence of BM from endometrial (2, 3) and ovarian tumors (4) seems to be rising. This increase in the incidence of BM may be explained partially by the fact that the incidence of these tumors is rising (2, 13, 29) . Also improved survival due to recent advances in combination treatment of the primary tumors and effective diagnostic equipment such as magnetic resonance imaging (MRI) and computerized tomography (CT) (30) may help to explain the increase in the diagnosis of BM.
The prognosis for patients with BM from gynecological malignancies is poor (1-6), and no study has ever suggested a definitive treatment. To analyze the factors that affect overall survival after therapy and to determine an optimal treatment regimen, we reviewed the medical charts of 25 patients with BM from gynecological tumors.
Materials and Methods
Between January 1982 and November 1999, 1391 patients with BM were treated at our Department of Radiation Oncology. Using a database of BM patients, we identified 25 women whose BM were from gynecological malignancies. All 25 patients were diagnosed and treated for primary and secondary tumors at our institution between July 1985 and November 1999.
We reviewed the medical records of these 25 patients and identified the following variables: primary tumor site, patient age at diagnosis of primary tumor, histology, stage of the primary tumor, and type of treatment used to manage the primary tumor. The tumor stage was determined using the International Federation of Gynecologists and Obstetricians (FIGO) system. We also identified the patients' ages at the time of BM diagnosis, the interval between the primary tumor diagnosis and the BM diagnosis, the symptoms at BM diagnosis, and whether the patient had controlled primary disease or systemic disease. Karnofsky Performance Score (KPS) was also recorded for each patient at the time of BM diagnosis.
Patients were classified using the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) classification, as proposed by Gaspar et al. (18) . The presence of BM was confirmed in all 25 patients with a CT or MRI scan of the brain. We counted the number of BM that developed in each patient. In addition, the histology of the BM was confirmed in 10 patients after biopsy or resection of the BM.
We evaluated the distribution patterns of the BM and the extent of the disease using the findings from the patients' MRI or CT scans. We also noted the type of therapy used to manage the BM. For the patients who received radiation therapy, we reviewed the treatment charts to identify the treatment regimens (technique, total dose, dose per fraction, and number of fractions), acute or chronic complications, and the treatment tolerance. The response to the treatment was identified radiographically in 9 patients who underwent a follow-up MRI scan after the end of treatment.
Finally, we recorded the date of death or last follow-up and the survival time from the date of detection of the BM for all the patients. Kaplan-Meier analysis was used to calculate median survival times for the entire study population, as well as by primary site, presence of systemic disease, control of primary, RPA class, number of BM, and BM treatment modality. The log rank test was used to determine if there were significant differences between the survival curves. The actuarial method was used to calculate the one and two year survival rates.
306
Mahmoud-Ahmed et al. The median age for the 25 study patients at diagnosis of the primary tumor was 43 years (range, 36 to 77 years). Most of the primary tumors were adenocarcinoma (n=20) while few had adenosquamous carcinoma (n=2) or squamous carcinoma (n=3). The median age at the diagnosis of BM was 46 years (range, 37 to 78 years), and the median interval between the diagnosis of the primary tumor and the diagnosis of the BM was 12.7 months (range, 0.25 to 106.5 months). All patients developed neurological symptoms that led to a diagnosis of BM. Loss of consciousness, seizures, motor weakness, and headache were the most common symptoms.
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Results
Characteristics of the Primary Tumor and Clinical Presentation of BM
At the time of the BM diagnosis, 13 patients had controlled primary disease, 5 had progressive primary disease, and 7 were newly diagnosed. Thirteen patients had systemic metastases with bone being the most common site of the systemic metastasis.
Patterns of BM
The 25 patients had a total of 136 lesions, and they ranged in diameter from 0.5 cm to 5.5 cm. The lesions were in the cerebral hemispheres in 19 patients and in both the cerebral and cerebellar hemispheres in 4 patients. The cerebellum was the only site of BM in 2 patients. Although metastases developed in all of the brain lobes, they occurred least often in the occipital lobe and most often in the frontal and temporal lobes.
Management and Outcome
The treatment for BM was whole brain radiation therapy (WBRT) in 11 patients, focal therapy (surgery and/or stereotactic radiosurgery [SRS]) in 6 patients and combination therapy (WBRT and surgery and/or SRS) in 8 patients.
Among the patients who underwent surgery, 7 had gross total resection and 2 had subtotal resection. Three patients had biopsy only and were included in WBRT group. The stereotactic radiosurgery was Linac-based in 3 patients, and 4 had Gamma Knife SRS. In the patients who received WBRT, the
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Technology At the time of this analysis, 8 patients had died from neurological disease, 2 from local disease, and 9 from systemic disease. Four of the 8 patients who died from neurological disease had local brain failure and 4 had new brain lesions. Patients who died from systemic disease had mainly advanced systemic lesions in lung or liver. The median survival for all 25 patients after the diagnosis of brain metastasis was 7.3 months (range, 1 to 88 months). The best survival was reported in patients with RTOG RPA class I, single brain metastasis or patients treated by combined therapy. Table II summarizes the survival data (median survival and 1-and 2-year survival rates) for 6 patient subgroups as well as P values of the log-rank test used to compare differences among the subgroups. Survival for four of the six patient groups is illustrated in Figures 1 through 4 .
Discussion
We studied a group of patients with a rare disease over a long period of time (17 years). The patients were offered different treatment modalities based on treatment availability. In our study, BM from gynecological malignancies accounted for only 1.79% of all patients with BM who had been treated at our facility since 1982 (25 of 1391 patients). This is consistent with other studies that have suggested that BM from gynecological tumors are rare. reviewed 15 studies that had a total of 2910 patients with BM. In these BM patients, 26 (0.89%) had the ovary as the primary tumor site, 24 (0.82%) had choriocarcinoma, 22 (0.76%) had endometrial carcinoma, and 15 (0.52%) had cervical carcinoma. None of our patients had BM from choriocarcinoma, and endometrial carcinoma was the most common primary site, accounting for 0.72% (10 of 1391 patients) of all cases of BM.
The prognosis for patients with endometrial carcinoma and BM is poor because the disease is usually widely disseminated by the time the BM develops (13). The presence of systemic disease seems to adversely affect patient outcome (1-12). In a study by Cormio et al. (3) , all patients had uncontrolled primary disease (recurrent or progressive) and 4 of 10 patients had disseminated disease. The median survival was only 1 month (range, 1-83). The majority of patients with ovarian tumors in two studies by Baker et al. when central nervous system involvement was diagnosed. Only 50% of cervical carcinoma patients with BM had systemic disease with median survival of 4 months for all the patients in the study (7). In our study, 52% of the patients had systemic disease in bone, lung or liver, and they lived for a shorter amount of time than did those without systemic metastases (6 versus 11 months, p= not significant [NS] ).
We decided to analyze patient survival using the RPA classification system because of evidence that suggests it is a useful tool in predicting survival. In a study of Radiation Therapy Oncology Group (RTOG) trials, RPA was used to classify patients with BM who were treated with radiation and other non-surgical modalities into 3 distinct prognostic groups according to the patients' pretreatment characteristics and disease factors (18). They reported a median survival of 7.1 months for patients with BM in RPA class I, 4.2 months for patients with BM in class II, and 2.3 months for patients with BM in class III. In our study, the survival seemed to be better. Patients with BM in class I lived for 16 months, those with BM in class II lived for 11 months and those with BM in class III lived for 3 months. This may be due to the difference in the primary tumor sites and may suggest a better survival for patients with BM from gynecological malignancies in comparison to the other sites.
Surgical resection followed by WBRT is considered by some oncologists to be the best treatment option for patients with single or resectable brain metastasis who have no other metastatic sites. Patchell et al. (19) demonstrated that patients with a single brain metastasis from a solid tumor who were treated with surgery plus radiotherapy lived longer, had a longer period of neurological improvement, and had a lower rate of recurrence of BM than patients who were treated with WBRT. Thus, patients with a single brain metastasis and controlled or absent extracranial tumor activity are generally treated with surgery and radiotherapy, especially when they are younger than 60. For patients with progressive extracranial disease, radiotherapy alone is sufficient palliative treatment (19-21, 25, 26) . Sneed et al. (22) suggested that SRS without WBRT can be used to treat up to 4 brain metastases. Noordijk et al. (21) concluded that combined treatment led to a better duration of survival (median 10 versus 6 months; P= .04). Currently, WBRT is considered the mainstay of palliation in patients with multiple or inoperable brain metastases. Radiation therapy improves neurological function in 50% of patients with brain metastases from solid tumors, but the median survival is poor (2 to 5 months) and 30% to 50% of the patients die as a result of their brain metastases (23,24). Rodriguez et al. (28) found a statistically significant survival advantage associated with the use of trimodality therapy (surgery, chemotherapy, and irradiation) in BM from ovarian carcinoma. They studied 14 patients treated for BM from ovarian carcinoma (WBRT=4, surgery + WBRT=1, WBRT + chemotherapy=6 and all three treatment modalities=3). The median survival was 3, 10, 7, and 16.5 months, respectively. In our study, the combination therapy (WBRT + surgery and/or SRS) was the best option, when used, for patients with BM from gynecological malignancies (median survival 11 months versus 7 for focal and 6 months for WBRT, P=NS). The patients with single BM had a better survival if compared to those with multiple BM (17 versus 3 months; P=.017).
Cormio et al. (3) reported a group of 10 patients with BM from endometrial carcinoma. Six patients receiving only steroids died within 1 month from the diagnosis. One patient received radiotherapy (survival of 3 months) and two underwent surgical resection of solitary metastasis followed by radiotherapy (survival of 28 and 83 months). Ikeda et al. (6) studied 8 patients with BM from cervical carcinoma. Three of them had surgical resection followed by WBRT, and the other 5 had only WBRT with 3 month survival in the entire group. Although survival in patients with BM from ovarian carcinoma in 32 women treated with WBRT was only 4 months (4), chemotherapy (27, 28) or radiosurgery (4) may prolong the survival in these patients. In our study, patients with BM from ovarian cancer seemed to have a better prognosis than those with endometrial or cervical cancer (median 12 versus 6 and 4 months). This might be due to the difference in the stage of the primary tumor and the type of treatment for the BM.
Although these findings corroborate other studies (1, 3-8, 28), our results should be viewed cautiously, as it is a small retrospective study of 25 patients treated over a 17-year period. Further studies are encouraged for patients with BM from gynecological malignancies.
Conclusion
Patients with gynecological malignancies who present with BM have a reasonable life expectancy after treatment of the BM. Although the number of the cases was small, patients with single brain lesion did better than those with multiple lesions. We encourage enrollment onto prospective clinical trials that may help us to better select therapies for future patients.
